Peter Schmid, Barts Cancer Institute, Queen Mary University, London
Real-time analysis of the BEGONIA trial at ESMO: Dato-DXd combined with immunotherapy demonstrates a 79% ORR in PD-L1-negative advanced TNBC, breaking through immunotherapy limitations and poised to reshape the first-line treatment paradigm.